White Paper: Performance Evaluation of the CE-IVD SOPHiA DDM™️ Dx RNAtarget Oncology Solution (ROS)

Published on 09/27/2022

< 1 min read

Tags:
Read our SOPHiA DDM™️ Dx ROS performance evaluation study and make confident data-driven decisions that improve patient care.

SOPHiA DDM™️ Dx ROS is a novel CE-IVD marked NGS assay for detecting gene fusion and exon skipping events from small lung cancer biopsy samples. A performance evaluation study demonstrates that, compared with existing RNA-based assays, SOPHiA DDM™️ Dx ROS provides accurate actionable clinical insights for healthcare professionals to make disease management decisions for patients with advanced lung cancer.

Sign Up To Our Newsletter

Enter your email address to join our mailing list and receive the latest news and updates from SOPHiA GENETICS. You can unsubscribe by using the link integrated with the communication at any time. By clicking to “sign up”, you agree that SOPHiA GENETICS will process your data in accordance with its Privacy Policy

pink dots icon

Related Posts

pink dots icon

Want to know more?
Get in touch with us.

Our client services team is on hand to help.
';